Tocilizumab trial failure highlights the complexity of COVID-19 inflammation

Negative findings from another tocilizumab trial in COVID-19 patients show there is still a lot to learn about which inflammatory pathway to target, researchers say . “Maybe blocking IL-6 is not the right way, and it could be that blocking TNF [tumour necrosis factor] will be effective, or blocking IL-1, or one of the other ...

Already a member?

Login to keep reading.

© 2021 the limbic